These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
13. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J; Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614 [TBL] [Abstract][Full Text] [Related]
14. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer]. MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030 [No Abstract] [Full Text] [Related]
19. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors]. Koopmans PP Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1726-9. PubMed ID: 14520797 [TBL] [Abstract][Full Text] [Related]
20. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort. Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775 [No Abstract] [Full Text] [Related] [Next] [New Search]